Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.
Structural Tailwinds
The cost of genomic sequencing has dropped from nearly $100mm per genome in 2002 to less than $1,000 in 2020. Adoption has continued to rise, as costs plummet (Source: National Human Genome Research Institute, Nov 2021).
Targeted Exposure
The ETF provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
Capital at Risk. All financial investments involve an element of risk. Therefore, the value of your investment and the income from it will vary and your initial investment amount cannot be guaranteed.
ETF Summary
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) seeks to invest in
companies that potentially stand to benefit from further advances in the field
of genomic science, such as companies involved in gene editing, genomic
sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
ETF Objective
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics v2 Index.
Regulatory
SFDR Classification
Article 6
UCITS Compliant
Yes
ISA Eligibility
Yes
SIPP Eligibility
Yes
UK Reporting Status
Yes
Authorized Participants & Market Makers
Citigroup Global Markets,
DRW Europe BV,
Flow Traders BV,
GHCO LLP,
HSBC Bank PLC,
Jane Street Financial Ltd,
Mirae Asset Securities UK Ltd,
Societe Generale SA,
Susquehanna Intl Ltd, Virtu Financial Ireland Ltd, JP Morgan Securities PLC
